How long can patients with mid-stage lung cancer usually live? It depends on the type

Regarding the survival of patients with mid-stage lung cancer, if they have EGFR mutations, they can survive 3 to 5 years by receiving targeted therapy; patients with small cell mid-stage lung cancer can survive 1 to 2 years.

We know that lung cancer is a very harmful disease and is very dangerous. So, how long can a person with mid-stage lung cancer usually live? Let's find out below!
There are many factors that affect the survival of patients with mid-stage lung cancer. First, it depends on what kind of treatment the patients have received. Second, it depends on what level of treatment the patients can tolerate based on their physical condition.
Generally speaking, mid-stage lung cancer refers to a situation where the patient's tumor diameter is greater than 5 cm and less than 7 cm, usually accompanied by hilar lymph node metastasis or mediastinal lymph node metastasis.
In addition, it also depends on the nature of the patient's pathology. If the patient has an EGFR mutation and receives currently advanced targeted therapy, the patient's survival period can generally be between 3 and 5 years.
For patients with mid-stage small cell lung cancer, the survival period is usually between 1 and 2 years.
In summary, the survival period of patients with mid-stage lung cancer depends on the severity of the patient's condition and the specific type of cancer. However, if the patient can be treated early, the treatment effect will be better and the survival period will be longer.